Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE

N Gaspar; L V Marshall; D Binner; R Herold; R Rousseau; P Blanc; R Capdeville; J Carleer; C Copland; Y Kerloeguen; K Norga; L Pacaud; M-A Sevaux; C Spadoni; J Sterba; F Ligas; T Taube; M Uttenreuther-Fischer; S Chioato; M A O'Connell; B Geoerger; J-Y Blay; J C Soria; S Kaye; B Wulff; L Brugières; G Vassal; A D J Pearson; Members of Working Group 1 of the Paediatric Platform of ACCELERATE

doi:10.1093/annonc/mdy002

Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE

Ann Oncol. 2018 Mar 1;29(3):766-771. doi: 10.1093/annonc/mdy002.

Authors

N Gaspar¹, L V Marshall², D Binner³, R Herold⁴, R Rousseau⁵, P Blanc⁶, R Capdeville⁷, J Carleer⁸, C Copland⁹, Y Kerloeguen¹⁰, K Norga¹¹, L Pacaud⁷, M-A Sevaux¹², C Spadoni¹³, J Sterba¹⁴, F Ligas⁴, T Taube¹⁵, M Uttenreuther-Fischer¹⁵, S Chioato¹⁶, M A O'Connell¹⁶, B Geoerger¹⁷, J-Y Blay¹⁸, J C Soria¹⁹, S Kaye²⁰, B Wulff²¹, L Brugières¹⁷, G Vassal²², A D J Pearson²; Members of Working Group 1 of the Paediatric Platform of ACCELERATE

Affiliations

¹ Department of Oncology for Children and Adolescents, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: nathalie.gaspar@gustaveroussy.fr.
² Paediatric and Adolescent Drug Development Team, Oak Centre for Children & Young People, The Royal Marsden Hospital & The Institute of Cancer Research, London, UK.
³ Create for Chloe and UK Representative for aPODD, European Medicines Agency, London, UK.
⁴ Product Development Scientific Support Department, European Medicines Agency, London, UK.
⁵ Gritstone Oncology, Inc., Emeryville, USA.
⁶ Imagine for Margo, Fourqueux, France.
⁷ Novartis AG, Basel, Switzerland.
⁸ Belgium Federal Agency for Medicines and Health Products, EUROSTATION, Brussels, Belgium.
⁹ Centre for English Language Teaching, University of York, York, UK.
¹⁰ Pharmaceuticals Division, PDOA, Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
¹¹ Paediatric and Adolescent Drug Development Team, Oak Centre for Children & Young People, The Royal Marsden Hospital & The Institute of Cancer Research, London, UK; Universitair Ziekenhuis Antwerpen, Edegem, Belgium.
¹² Jeunes Solidarité Cancer, Paris, France.
¹³ aPODD Foundation, City Point, London, UK.
¹⁴ Pediatric Oncology Department, University Hospital Brno, School of Medicine Masaryk University Brno, Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, ICRC Brno, St. Anna University Hospital Brno, Czech Republic.
¹⁵ Boehringer Ingelheim, Pharma GmbH&Co KG, TA Oncology, Biberach, Germany.
¹⁶ Regulatory Strategy Oncology, Pfizer Italia, Milano, Italy.
¹⁷ Department of Oncology for Children and Adolescents, Gustave Roussy Cancer Campus, Villejuif, France.
¹⁸ Centre Léon Bérard and University Claude Bernard Lyon 1, Lyon.
¹⁹ Drug Development Department (DITEP), Gustave Roussy, Villejuif and University Paris-Sud, Orsay, France.
²⁰ Adult Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, London, UK.
²¹ Paediatric Haematology/Oncology, Clinical Research/Paediatric Drug Development, University Childreńs Hospital III Hufelandstraße, Essen, Germany.
²² Department of Clinical Research, Gustave Roussy, Villejuif and Paris-Sud University, Le Kremlin-Bicêtre, France.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Antineoplastic Agents / therapeutic use*
Clinical Trials as Topic*
Drug Development*
Female
Humans
Male
Neoplasms / drug therapy*
Young Adult

Substances

Antineoplastic Agents